The aim of the present study was to reveal the effect of a
xanthine oxidoreductase (XOR) inhibitor,
topiroxostat (Top), compared with another inhibitor,
febuxostat (Feb), in an
adenine-induced renal injury model. We used human liver-type
fatty acid-binding protein (L-FABP) chromosomal transgenic mice, and urinary L-FABP, a
biomarker of tubulointerstitial damage, was used to evaluate tubulointerstitial damage. Male transgenic mice (n = 24) were fed a 0.2% (wt/wt)
adenine-containing diet. Two weeks after the start of this diet, renal dysfunction was confirmed, and the mice were divided into the following four groups: the
adenine group was given only the diet containing
adenine, and the Feb, high-dose Top (Top-H), and low-dose Top (Top-L) groups were given diets containing Feb (3 mg/kg), Top-H (3 mg/kg), and Top-L (1 mg/kg) in addition to
adenine for another 2 wk. After withdrawal of the
adenine diet, each medication was continued for 2 wk. Serum
creatinine levels, the degree of macrophage infiltration, tubulointerstitial damage, renal
fibrosis, urinary
15-F2t-isoprostane levels, and renal XOR activity were significantly attenuated in the kidneys of the Feb, Top-L, and Top-H groups compared with the
adenine group. Serum
creatinine levels in the Top-L and Top-H groups as well as renal XOR in the Top-H group were significantly lower than those in the Feb group. Urinary excretion of L-FABP in both the Top-H and Top-L groups was significantly lower than in the
adenine and Feb groups. In conclusion, Top attenuated renal damage in an
adenine-induced renal injury model.